Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta)

Author:

Trimpert Jakob1ORCID,Adler Julia M.12ORCID,Eschke Kathrin1,Abdelgawad Azza1,Firsching Theresa C.3ORCID,Ebert Nadine45,Thao Tran Thi Nhu456,Gruber Achim D.3ORCID,Thiel Volker45ORCID,Osterrieder Nikolaus17ORCID,Kunec Dusan1ORCID

Affiliation:

1. Institut für Virologie, Freie Universität Berlin, Berlin, Germany.

2. Department of Infectious Diseases and Respiratory Medicine, Charité, Universitätsmedizin Berlin, Berlin, Germany.

3. Institut für Tierpathologie, Freie Universität Berlin, Berlin, Germany.

4. Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland.

5. Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.

6. Graduate School for Biomedical Science, University of Bern, Bern, Switzerland.

7. Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Kowloon, Hong Kong.

Abstract

A single intranasal vaccination with live attenuated virus provides protection against VOC B.1.1.7 (Alpha) and B.1.351 (Beta).

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference42 articles.

1. World Health Organization Draft landscape of COVID-19 candidate vaccines (2021); https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.

2. Medicines and Healthcare products Regulatory Agency UK medicines regulator gives approval for first UK COVID-19 vaccine (2020); https://www.gov.uk/government/news/uk-medicines-regulator-gives-approval-for-first-uk-covid-19-vaccine.

3. FDA FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine (2020); https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19.

4. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

5. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3